HUM vs PHG vs CRVL Stock Comparison

Humana, Koninklijke Philips and Corvel Prices as of Nov 13, 2026 Peers: Industry group
HUM Humana Inc
$450.46 +5.4% 1M +90.3% 1Y
Market cap
$55.42B
P/E
44.5x
Revenue (TTM)
$154.19B
Div. yield
–
Managed Care Healthcare
3 wins
PHG Koninklijke Philips Nv
$30.35 +21.4% 1M +4.9% 1Y
Market cap
$28.63B
P/E
15.0x
Revenue (TTM)
$30.13B
Div. yield
–
Diagnostic Equipment Healthcare
6 wins
CRVL Corvel Corp
$85.69 +6.6% 1M +16.6% 1Y
Market cap
$4.42B
P/E
36.4x
Revenue (TTM)
$1.01B
Div. yield
–
Managed Care Healthcare
2 wins

Head to Head

11 decided of 12

Koninklijke Philips leads on 6 of the 12 questions below (Koninklijke Philips 6, Humana 3, Corvel 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionHUMPHGCRVLLeader
Larger companyMarket capitalisation $55.42B $28.63B $4.42B HUM
Cheaper on earningsLower P/E, profitable companies only 44.5x 15.0x 36.4x PHG
Cheaper on forward earningsLower price / next fiscal year consensus EPS 50.2x 15.3x — PHG
Faster revenue growthRevenue growth, trailing twelve months +22.0% +53.4% +8.3% PHG
More profitableNet margin, trailing twelve months 0.8% 6.3% 12.0% CRVL
Better return on capitalReturn on invested capital 5.5% 12.1% — PHG
Less leveragedLower net debt / EBITDA -3.9x 1.7x — HUM
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +90.3% +4.9% +16.6% HUM
Better 5-year returnAnnualised price return, 5 years +0.2%/yr -8.6%/yr +6.0%/yr CRVL
Less volatileAnnualised volatility, 1 year 47.3% 29.5% 44.1% PHG
Higher overall scoreMean of the five percentile scores vs peers 55/100 80/100 64/100 PHG

Percentile Scorecard

HUMPHGCRVL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisHUMPHGCRVL
Valuation 69 #9 of 27 98 #6 of 243 27 #20 of 27
Growth 44 #15 of 26 99 #3 of 228 60 #11 of 26
Profitability 48 #14 of 26 92 #18 of 222 92 #3 of 26
Financial Health 80 #6 of 26 30 #175 of 248 96 #2 of 26
Shareholder Returns 35 #12 of 18 81 #31 of 158 47 #10 of 18
Overall 55 80 64
  • HUM ranked among 27 companies in Healthcare Payers and Distributors
  • PHG ranked among 252 companies in Medical Devices and Diagnostics
  • CRVL ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodHUMPHGCRVLSPY
1 month +5.4%+21.4%+6.6% -2.0%
3 months +15.6%+11.3%+30.4% -2.8%
6 months +47.6%+20.3%+50.0% +2.0%
Year to date +75.9%+12.1%+26.6% +10.6%
1 year +90.3%+4.9%+16.6% +12.2%
3 years -10.3%+45.8%+20.0% +68.1%
3 years, per year -3.5%+13.4%+6.3% +18.9%
5 years +1.1%-36.3%+34.0% +61.4%
5 years, per year +0.2%-8.6%+6.0% +10.1%
10 years +133.2%+4.2%+703.3% +248.5%
10 years, per year +8.8%+0.4%+23.2% +13.3%

Risk

MeasureHUMPHGCRVLSPY
Volatility, 1Y 47.3%29.5%44.1% 13.6%
Downside volatility, 1Y 50.6%27.6%53.6% 13.9%
Beta vs S&P 500, 1Y 0.520.840.06 1.00
Return / volatility, 1Y 1.910.170.38 0.90
Max drawdown, 5Y -70.9%-72.2%-64.2% -25.4%
From 52-week high 0.0%-7.8%-1.9% -3.2%
52-week high $450.46$32.91$87.38 $779.14
52-week low $163.67$23.81$46.00 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleHUMPHGCRVL
P/E now vs peer median 43.4xmedian 25.2x 15.1xmedian 26.5x 35.6xmedian 25.2x
P/S now vs peer median 0.4xmedian 0.4x 1.0xmedian 2.7x 4.3xmedian 0.4x
EV/EBITDA now vs peer median 13.3xmedian 14.5x 8.5xmedian 18.4x 20.7xmedian 14.5x
P/FCF now vs peer median 17.2xmedian 16.5x 5.6xmedian 25.4x 33.8xmedian 16.5x
P/B now vs peer median 2.9xmedian 2.7x 2.2xmedian 2.5x 10.0xmedian 2.7x
PEG now vs peer median -1.73median 1.72 0.22median 0.98 1.91median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsHUMPHGCRVL
Revenue $154.19B $30.13B $1.01B
Gross profit $20.06B $16.13B $258.02M
Operating income $2.38B $2.79B $161.13M
Net income $1.26B $1.45B $121.52M
Free cash flow $3.14B $5.23B $127.86M
R&D – $1.99B –
EPS (diluted) $10.23 $1.98 $2.40
Cash & equivalents $6.94B $3.12B $269.99M
Total debt $12.92B $10.22B –
Shares (diluted) 121.83M 962.50M 50.69M
Enterprise value -$35.43B $16.90B $3.43B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricHUMPHGCRVL
P/E 43.4x 15.1x 35.6x
P/FCF 17.2x 5.6x 33.8x
P/Operating cash flow 14.5x 8.2x 26.2x
P/S 0.4x 1.0x 4.3x
P/B 2.9x 2.2x 10.0x
P/Tangible book 2.9x 2.8x 10.0x
EV/EBITDA 13.3x 8.5x 20.7x
EV/EBIT 17.6x 13.0x 25.1x
EV/Revenue 0.3x 1.2x 4.0x
EV/FCF 13.3x 6.9x 31.7x
EV/Operating cash flow 11.2x 10.2x 24.5x
PEG (3Y EPS CAGR) -1.73 0.22 1.91

Growth

14 metrics
MetricHUMPHGCRVL
Revenue growth (1Y) 22.0% 53.4% 8.3%
Revenue CAGR (3Y) 14.6% 15.1% 10.4%
Gross profit growth (1Y) 6.2% 76.3% 14.2%
Gross profit CAGR (3Y) 3.4% 4.0% 15.3%
Operating income growth (1Y) -19.8% 49.6% 19.1%
Operating income CAGR (3Y) -19.0% 337.8% 19.3%
Net income growth (1Y) -2.9% 444.3% 15.4%
Net income CAGR (3Y) -25.2% 45.2% 17.6%
EPS growth (1Y) -4.3% 177.7% 17.7%
EPS CAGR (3Y) -25.1% 69.9% 18.6%
Operating cash flow growth (1Y) 82.4% 154.0% 14.2%
Operating cash flow CAGR (3Y) -14.6% 34.9% 19.3%
Free cash flow growth (1Y) 102.9% 74.5% 26.4%
Free cash flow CAGR (3Y) -14.3% 35.7% 21.1%

Profitability

14 metrics
MetricHUMPHGCRVL
Gross margin 13.0% 53.5% 25.5%
EBITDA margin 2.0% 14.1% 19.3%
Operating margin 1.5% 9.2% 15.9%
Pretax margin 1.1% 8.7% 15.9%
Net margin 0.8% 6.3% 12.0%
FCF margin 2.0% 17.4% 12.6%
Operating cash flow margin 2.4% 11.8% 16.3%
Return on equity 6.6% 13.2% 29.0%
Return on assets 2.2% 5.5% 17.3%
Return on invested capital 5.5% 12.1% –
Return on capital employed 7.2% 12.6% 36.3%
Asset turnover 2.7x 1.0x 1.4x
Cash conversion (OCF / net income) 3.0x 2.4x 1.4x
Stock comp / revenue 0.1% 0.5% 0.5%

Financial Health

11 metrics
MetricHUMPHGCRVL
Debt / assets 22.4% 32.2% –
Debt / equity 0.7x 0.8x –
Net debt / EBITDA -3.9x 1.7x –
Debt / FCF 4.1x 2.0x –
Liabilities / assets 67.0% 58.7% 39.7%
Equity / assets 33.0% 41.3% 60.3%
Interest coverage 3.2x 6.5x –
Current ratio 1.6x 1.3x 2.0x
Quick ratio 1.2x 0.8x 1.6x
Cash ratio 1.0x 0.4x 1.0x
Altman Z-score 4.75 – 13.88

Shareholder Returns

7 metrics
MetricHUMPHGCRVL
Dividend yield 0.8% 3.3% –
Net buyback yield 0.3% -0.7% 0.7%
Shareholder yield 1.1% 2.5% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusHUMPHGCRVL
Forward P/E 50.2xFY2026 15.3xFY2026 –
EPS, next fiscal year $8.98FY2026 $1.99FY2026 –
EPS growth, next FY -47.6%FY2026 +7.0%FY2026 –
EPS growth, the year after +95.0% -10.6% –
Revenue, next fiscal year $167.02BFY2026 $21.44BFY2026 –
Revenue growth, next FY +28.8%FY2026 +0.9%FY2026 –
Revenue growth, the year after +11.4% -7.8% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersHUMPHGCRVL
Held by institutions 98.6% 5.4% 54.5%
Institutions holding 930 365 288
Change in shares held, QoQ +2.7% +0.8% +2.3%
Institutions buying 560 267 172
Institutions selling 267 76 72
Buyers to sellers 2.10 3.51 2.39

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

HUMPHGCRVL
HUM 1.00 0.02 0.12
PHG 0.02 1.00 0.12
CRVL 0.12 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, HUM, PHG and CRVL?

Humana (HUM) is the largest by market capitalisation: Humana (HUM) $55.42B, Koninklijke Philips (PHG) $28.63B, Corvel (CRVL) $4.42B.

Which stock is cheaper, HUM, PHG and CRVL?

Koninklijke Philips (PHG) trades on the lowest price-to-earnings ratio (Humana (HUM) 44.5x, Koninklijke Philips (PHG) 15.0x, Corvel (CRVL) 36.4x). On next year's consensus earnings, Koninklijke Philips (PHG) is cheapest (Humana (HUM) 50.2x, Koninklijke Philips (PHG) 15.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Koninklijke Philips (PHG) grew revenue fastest over the trailing twelve months: Humana (HUM) +22.0%, Koninklijke Philips (PHG) +53.4%, Corvel (CRVL) +8.3%.

Which company is more profitable?

Corvel (CRVL) has the highest net margin (Humana (HUM) 0.8%, Koninklijke Philips (PHG) 6.3%, Corvel (CRVL) 12.0%). On return on invested capital, Koninklijke Philips (PHG) leads (Humana (HUM) 5.5%, Koninklijke Philips (PHG) 12.1%).

Which stock has performed better?

Over the past year Humana (HUM) returned the most: Humana (HUM) +90.3%, Koninklijke Philips (PHG) +4.9%, Corvel (CRVL) +16.6%. Over five years, Corvel (CRVL) compounded fastest (Humana (HUM) +0.2%/yr, Koninklijke Philips (PHG) -8.6%/yr, Corvel (CRVL) +6.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Humana (HUM) 47.3%, Koninklijke Philips (PHG) 29.5%, Corvel (CRVL) 44.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, HUM, PHG and CRVL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.